SAR Stock Overview
A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sareum Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.20 |
| 52 Week High | UK£0.53 |
| 52 Week Low | UK£0.10 |
| Beta | -0.93 |
| 1 Month Change | -16.33% |
| 3 Month Change | -19.61% |
| 1 Year Change | -55.91% |
| 3 Year Change | -88.92% |
| 5 Year Change | 1.23% |
| Change since IPO | -86.33% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation
Aug 24
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate
Apr 27Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
Aug 06We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth
Apr 22Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
Jan 06We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate
Aug 31We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely
May 07What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?
Dec 23
Shareholder Returns
| SAR | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -10.9% | 2.9% | 2.0% |
| 1Y | -55.9% | 3.5% | 10.8% |
Return vs Industry: SAR underperformed the UK Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: SAR underperformed the UK Market which returned 10.8% over the past year.
Price Volatility
| SAR volatility | |
|---|---|
| SAR Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SAR has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SAR's weekly volatility has decreased from 17% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | n/a | www.sareum.com |
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc Fundamentals Summary
| SAR fundamental statistics | |
|---|---|
| Market cap | UK£25.57m |
| Earnings (TTM) | -UK£3.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.5x
P/E RatioIs SAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAR income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.42m |
| Earnings | -UK£3.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 23:56 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sareum Holdings plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Hall | Hardman & Co. |
| Yi-Ling Liu | Hybridan LLP |
| Miles Dixon | Peel Hunt LLP |